Nateglinide, 98%, an insulin secretagog agent

Name: Nateglinide, 98%, an insulin secretagog agent | 105816-04-4
Brand: J&K Chemical
SKU: JK586681_1_G
Price: 130.0 USD
Availability: InStock

Cat. No JK586681_1_G

Vendor: J&K Chemical

Product Information

Product Name

Nateglinide, 98%, an insulin secretagog agent

Brand Name

J&K

Product Number

586681

CAS

105816-04-4

SDS Document

View/Download

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

5311309

IUPAC Name

(2R)-3-phenyl-2-(4-propan-2-ylcyclohexanecarbonyl)aminopropanoic acid

InChI Key

OELFLUMRDSZNSF-OFLPRAFFSA-N

SMILES

CC(C)C1CCC(CC1)C(=O)NC@H(CC2=CC=CC=C2)C(=O)O

Safety Information

Storage Condition

Freezer -20℃

References Data Source From Pubchem

S73 | METXBIODB | Metabolite Reaction Database from BioTransformer

Publication Date: 2026

DOI: 10.5281/zenodo.4056560

Investigation of resolving sets in the molecular structures of hypoglycemia medications

Publication Name: Chemical Papers

Publication Date: 2025-08-23

DOI: 10.1007/s11696-025-04289-w

Beware the Receptor Variants

Publication Name: Journal of Medicinal Chemistry

Publication Date: 2023-11-17

DOI: 10.1021/acs.jmedchem.3c02026

Discovery of Potent Agonists for the Predominant Variant of the Orphan MAS-Related G Protein-Coupled Receptor X4 (MRGPRX4)

Publication Name: Journal of Medicinal Chemistry

Publication Date: 2023-11-15

DOI: 10.1021/acs.jmedchem.3c01013

Drug combinations identified by high-throughput screening promote cell cycle transition and upregulate Smad pathways in myeloma

Publication Name: Cancer Letters

Publication Date: 2023-08-01

DOI: 10.1016/j.canlet.2023.216284

Nateglinide, 98%, an insulin secretagog agent

Product Information

General Information

Safety Information

References Data Source From Pubchem

S73 | METXBIODB | Metabolite Reaction Database from BioTransformer

Investigation of resolving sets in the molecular structures of hypoglycemia medications

Beware the Receptor Variants

Discovery of Potent Agonists for the Predominant Variant of the Orphan MAS-Related G Protein-Coupled Receptor X4 (MRGPRX4)

Drug combinations identified by high-throughput screening promote cell cycle transition and upregulate Smad pathways in myeloma